# INmune Bio and Quantum Computing Partner to Advance Alzheimer's Drug Research

- URL: https://stocks.freetheai.org/news/inmune-bio-and-quantum-computing-partner-to-advance-alzheimer-s-drug-research-716c67
- Published: 2026-10-14T12:45:35Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:INMB](https://stocks.freetheai.org/symbols/NASDAQ-INMB), [NASDAQ:QUBT](https://stocks.freetheai.org/symbols/NASDAQ-QUBT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

INmune Bio Inc. (INMB) has partnered with Quantum Computing Inc. (QUBT) to apply quantum computing, artificial intelligence, and data analytics to its drug research. The collaboration will analyze clinical and pre-clinical data from four trials alongside public biomedical datasets to identify potential new applications and biomarkers for INmune Bio's investigational Alzheimer's treatment, XPro.

The initial Stage 1 project represents Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotechnology sector. The process utilizes the Dirac-3S entropy quantum optimization machine to process complex datasets and pinpoint conditions driven by the same inflammation biology targeted by XPro, specifically focusing on soluble tumor necrosis factor. The initial strategy aims to target rare diseases where clinical trials can be smaller, faster, and qualify for pediatric approvals.

The companies plan to evaluate the effectiveness of quantum optimization by benchmarking results from the Dirac-3S machine against standard statistical and machine-learning techniques. Investors and industry observers will monitor whether this discovery workflow successfully prioritizes new therapeutic indications and whether INmune Bio exercises its options for additional work under the collaboration agreement.

## Key points

- INmune Bio Inc. and Quantum Computing Inc. have launched a collaboration to use quantum computing and AI to explore new applications for Alzheimer's candidate XPro.
- The Stage 1 agreement marks Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotechnology market.
- The analysis will process pre-clinical and clinical data from four trials using the Dirac-3S quantum optimization machine alongside conventional analytics.
- Results from the quantum computing machine will be benchmarked against standard statistical and machine-learning methods.
- The agreement includes options for additional work as INmune Bio advances its clinical development pipeline.

## Questions and answers

### Why are INmune Bio and Quantum Computing partnering?

The companies are collaborating to use quantum computing, AI, and data analytics to discover new disease applications and biomarkers for INmune Bio's Alzheimer's drug candidate, XPro.

### What machine is Quantum Computing Inc. using for the INmune Bio project?

Quantum Computing Inc. is using its Dirac-3S entropy quantum optimization machine to analyze INmune Bio's clinical datasets alongside public biomedical data.

### Is this Quantum Computing Inc.'s first biotech customer?

Yes, the Stage 1 agreement represents Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotechnology market.